CSIMarket Company Name, Ticker, Industry, else..
Heron Therapeutics Inc   (NASDAQ: HRTX)
Other Ticker:  
 


 

Heron Therapeutics Inc

HRTX's Financial Statements and Analysis



Heron Therapeutics Inc increased third quarter of 2025 net loss per share of $-0.10 compare to net loss per share of $-0.03 recorded in the same quarter a year ago a decrease compare to $-0.02 realized in previous quarter.


third quarter of 2025
Earnings Per Share Revenues
$ -0.1 $  37 Mill
$-0.07     $+5M     +15.29 %



Heron Therapeutics Inc 's Revenue rose by 15.29 % in third quarter of 2025 (Sep 30 2025) year on year, to $37 million and advanced by 2.63 % sequentially.


Heron Therapeutics Inc is

More on HRTX's Income Statement



Heron Therapeutics Inc in the third quarter of 2025 recorded net loss of $-17.495 million, an increase from net loss of $-4.848 million in III. Quarter a year ago.

Sequentially net loss advanced

More on HRTX's Growth

Heron Therapeutics Inc Inventories
Inventories grew by 52.39 % to $70 million from III. Quarter a year ago, sequentially inventories fell by -4.03 %. HRTX's Cash flow In the third quarter of 2025 company's net cash flow was $27 million


Heron Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Heron Therapeutics Inc payed $ -0.18 cash per share, on a free-cash flow basis .

.


Company issued 16.33 million shares or 10.60 % in Sep 30 2025.


• More on HRTX's Dividends

 Market Capitalization (Millions) 187
 Shares Outstanding (Millions) 170
 Total Debt (Millions $) 32
 Revenue (TTM) (Millions $) 154
 Net Income (TTM) (Millions $) -14
 Cash Flow (TTM) (Millions $) 17
 Capital Exp. (TTM) (Millions $) -1
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 328




Heron Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Heron Therapeutics Inc had negative $ -0.18 cash flow per share, on a free-cash flow basis .

.


Company issued 16.33 million shares or 10.60 % in Sep 30 2025.


• More on HRTX's Balance Sheets

 Market Capitalization (Millions) 187
 Shares Outstanding (Millions) 170
 Total Debt (Millions $) 32
 Revenue (TTM) (Millions $) 154
 Net Income (TTM) (Millions $) -14
 Cash Flow (TTM) (Millions $) 17
 Capital Exp. (TTM) (Millions $) -1
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 328
   


  News about Heron Therapeutics Inc Earnings

Heron Therapeutics Inc: Unraveling the Mystery Behind Its Recent Stock Decline and Exploring Key Financial Metrics



In the ever-evolving world of finance, keeping track of a company's performance is crucial for investors and industry analysts. One such company that has experienced notable changes in recent trading sessions is Heron Therapeutics Inc. This article aims to shed light on the stock's recent decline, year-to-date performance, and provide an overview of the key financial metrics for the company.
Declining Stock Performance:
Over the course of the last five trading days, Heron Therapeutics Inc's stock experienced a significant downturn, falling by -20.89%. This decline adds to its year-to-date performance, which currently stands at -75.91%. Such a drop raises concerns among investors and undersc...

Heron Therapeutics Inc Faces Persistent Losses with a Shortfall of $-0.35 per Share Despite Revenue Growth in April-June 2023 Period

Heron Therapeutics Inc (HR...

1. Heron Therapeutics Inc. Generates Impressive Revenue Surge, but Profitability Eludes in Recent Fiscal Period

Heron Therapeutics Inc., a major pharmaceutical preparations company, recently announced in their first quarter financial report for 2023 that they experienced a surge in revenue by 26.252% to $29.62 million compared to the same period from the previous year. While this may seem like positive news, it?s important to note that the company lost money at $-0.27 per share. This is a significant increase in deficit from the preceding period which was $-0.15 per share, and their revenue also decreased by -1.375% from $30.03 million.
Despite the significant loss in earnings per share, Heron Therapeutics remains focused on improving their expansion prospects by increasing expenditures, while also trying to offse...


Date modified: 2025-11-04T21:10:13+00:00




Help

About us

Terms of Use

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2025 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.